International Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network

国际孕产妇、青少年和儿科治疗临床试验网络

• 批准号: 10306320
• 负责人: Grace M Aldrovandi
• 金额: $ 366.44万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-01-01 至 2027-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10306320
• 关键词: Address; Adolescent; Affect; Anti-Retroviral Agents; Area; Biological Assay; Blood Volume; Caring; Child; Childhood; Clinical; Clinical Trials; Clinical Trials Network; Collaborations; Consultations; Development; Diagnosis; Disease remission; Drug resistance; Ensure; Epidemic; Evaluation; Formulation; Genetic; Goals; Guidelines; HIV; HIV/TB; Immune response; Infant; Infection; Infrastructure; International; International Maternal Pediatric Adolescent AIDS Clinical Trials; Interruption; Intervention; Knowledge; Label; Laboratories; Laboratory Research; Laboratory Study; Leadership; Licensure; Measurement; Methodology; Monitor; Multi-Drug Resistance; Pathogenesis; Pharmacology; Populations at Risk; Pregnant Women; Prevention; Reproducibility; Research; Research Personnel; Research Priority; Resource-limited setting; Specimen; Technology; Testing; Therapeutic Clinical Trial; Total Quality Management; Training Programs; Tuberculosis; United States National Institutes of Health; Vertical Disease Transmission; Viral Load result; Vision; Vulnerable Populations; Work; antiretroviral therapy; assay development; base; clinical care; co-infection; comorbidity; data management; design; high standard; improved; innovation; interest; laboratory experience; laboratory experiment; novel; novel strategies; operation; programs; reconstruction; stem; study population; success; transmission process

ABSTRACT The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network has significantly advanced efforts to stem the global HIV epidemic among pregnant women, infants, children and adolescents through the conduct of high-quality clinical trials. The IMPAACT vision and overall goal is to end the worldwide HIV epidemic among these vulnerable populations. To achieve this goal, IMPAACT will evaluate novel and durable treatments for both HIV and TB, to establish strategies for antiretroviral treatment (ART)-free remission, and to address the complications, co-morbidities, and co-infections affecting these HIV-infected and at-risk populations of interest. The results of our studies have contributed to licensure or labeling changes for new antiretrovirals/formulations for use in HIV-infected pregnant women, infants and children and influenced international and US guidelines for clinical care in these vulnerable populations. In addition to generating concrete evidence in these areas, IMPAACT's work has served to build much needed research and laboratory capacity in resource-limited settings, where burden of the HIV epidemic remains the greatest. The IMPAACT Laboratory Center has been integral to the Network's success in defining the standards of care for HIV infected pregnant women, children and adolescents. Many of the mechanistic underpinnings that explain the success of IMPAACT clinical trials are managed and discovered by IMPAACT Laboratory Center investigators. In this competitive renewal of the IMPAACT Laboratory Center, we propose a work closely the Operations Center and the Statistical and Data Management Center to develop, implement and evaluate the laboratory activities necessary to accomplish IMPAACT's research agenda. Further, the Laboratory Center will ensure that there are relevant state-of-the-art expertise and technologies and to oversee all laboratory operations confirming that all laboratory results are consistent, reproducible and can support study reconstruction.

摘要